Beilai Bio
Irvine
About Beilai Bio
Beilai Bio is a clinical-stage biopharmaceutical company focused on the development of stem cell therapeutics for various diseases, particularly those with high unmet medical needs. Its established technology platforms allow them to produce clinical-grade "off-the-shelf" Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) from an unlimited supply of cord tissues that are traditionally regarded as medical waste.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $47.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2022)
- Website: baylxinc.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/beilai-bio-60244 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.